Aktuelle smitsomme sygdomme
Søgeord (rsv) valgt.
38 emner vises.
Medscape Infectious Diseases, 9.10.2024
Tilføjet 9.10.2024
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the... Reuters Health Information
Læs mereBrechje de Gier, Jan van de Kassteele, Liselotte van Asten, Annelot F Schoffelen, ISIS-AR study group, Mariette Hooiveld, Margreet JM te Wierik, Nina M van Sorge and Hester E de Melker
Eurosurveillance latest updates, 5.10.2024
Tilføjet 5.10.2024
BackgroundAfter most COVID-19 pandemic control measures were lifted in 2022, many infectious diseases re-emerged. An increase in invasive group A streptococcal (iGAS) infections among adults and young children was reported by several countries. Viral infections including influenza and varicella, known risk factors for iGAS infection, also increased. AimTo estimate the proportion of GAS skin and soft tissue infections (SSTI) and pneumonia/sepsis in children (≤ 5 years) attributable to varicella, and the proportion of GAS pneumonia/sepsis in children and adults attributable to potentially predisposing respiratory viruses influenza A and B, RSV, hMPV and SARS-CoV-2 in the Netherlands. MethodsWe performed time series regression using weekly data on respiratory viruses, varicella and non-invasive GAS infections and GAS isolates cultured from blood, lower airways, skin, pus and wounds, from January 2010 to March 2023. ResultsIn 2010–19, 50% (95% CI: 36–64) of GAS SSTI in children were attributable to varicella. Between January 2022 and March 2023, 34% (95% CI: 24–43) of GAS SSTI cases were attributable to varicella. Of iGAS pneumonia/sepsis between January 2022 and March 2023, 34% (95% CI: 20–49) and 25% (95% CI: 18–32) was attributable to respiratory virus infections in children and adults, respectively, with the largest contributor (17%) being influenza A. ConclusionsPredisposing viral infections likely contributed to, but cannot fully explain, the observed iGAS increase among children and adults in 2022–23 in the Netherlands. Public health measures to control viral infections, such as vaccination against varicella or influenza, might reduce the iGAS disease burden.
Læs mereMedscape Infectious Diseases, 2.10.2024
Tilføjet 2.10.2024
The World Health Organization on Tuesday recommended vaccinating pregnant women and administering infants with an antibody to prevent severe respiratory synctial virus (RSV)... Reuters Health Information
Læs mereMorbidity and Mortality Weekly Report (MMWR), 27.09.2024
Tilføjet 27.09.2024
This report describes the percentage of infants protected against respiratory syncytial virus from maternal RSV vaccination, nirsevimab, or both.
Læs mereMichael Stucki, Golda Lenzin, Philipp KA Agyeman, Klara M Posfay-Barbe, Nicole Ritz, Johannes Trück, Angela Fallegger, Susanne G Oberle, Oliver Martyn and Simon Wieser
Eurosurveillance latest updates, 27.09.2024
Tilføjet 27.09.2024
BackgroundRespiratory syncytial virus (RSV) is a leading cause of acute respiratory infections and hospitalisations in infants (age 18 years); 7.2% of cases required intensive care unit stay. Mean inpatient medical costs were estimated at EUR 8,046. Most (90.8%) hospitalised infants with RSV were born after 35 weeks of gestation without bronchopulmonary dysplasia or congenital heart disease. Low birth weight, gestational age and congenital disorders were associated with a higher risk for hospitalisation. ConclusionsRSV leads to a substantial number of hospitalisations and peaks in hospital capacity utilisation. Measures to protect all infants from an RSV hospitalisation are essential in addressing this public health challenge.
Læs mereMedscape Infectious Diseases, 19.09.2024
Tilføjet 19.09.2024
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a... Reuters Health Information
Læs mereECDC
ECDC COVID-19 updates, 18.09.2024
Tilføjet 18.09.2024
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mereMedscape Infectious Diseases, 14.09.2024
Tilføjet 14.09.2024
Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said. Medscape Medical News
Læs mereMedscape Infectious Diseases, 16.08.2024
Tilføjet 16.08.2024
Pfizer said on Monday its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a late-stage study of four groups of adults aged 18 and... Reuters Health Information
Læs mereMedscape Infectious Diseases, 13.08.2024
Tilføjet 13.08.2024
Correct timing for RSV testing and updated recommendations for three FDA-approved vaccines can reduce adult hospitalizations for this insidious infection. Medscape
Læs mereLea Gur-Arie, Michal Stein, Hanna Sefty, Ilana S Fratty, Ital Nemet, Limor Kliker, Nofar Atari, Neta S Zuckerman, Alina Rosenberg, Heftziba Ivgi, Orit Golan-Shany, Nadav Sorek, Orna Schwartz-Harari, Michal Bromberg, Lital Keinan-Boker, Michal Mandelboim, Aharona Glatman-Freedman and on behalf of the Israeli Respiratory Viruses Hospital Laboratory Network (IRVHLN)
Eurosurveillance latest updates, 9.08.2024
Tilføjet 9.08.2024
BackgroundA new respiratory virus surveillance platform, based on nationwide hospital laboratory data, was established in Israel during the COVID-19 pandemic. AimWe aimed to evaluate the performance of this platform with respect to the detection of influenza and respiratory syncytial virus (RSV) from week 36 in 2020 to week 15 in 2023, and how it fits with the World Health Organization (WHO) mosaic surveillance framework. MethodsData of respiratory samples from hospitalised patients sent for laboratory confirmation of influenza virus or RSV from 25 general hospital laboratories nationwide were collected. We analysed the weekly number and percentage of samples positive for influenza virus or RSV vis-à-vis SARS-CoV-2 activity and compared data from the new surveillance platform with existing surveillance platforms. Using data in the new surveillance platform, we analysed early stages of a 2021 out-of-season RSV outbreak and evaluated the capabilities of the new surveillance system with respect to objectives and domains of the WHO mosaic framework. ResultsThe new hospital-laboratory surveillance platform captured the activity of influenza virus and RSV, provided crucial data when outpatient sentinel surveillance was not operational and supported an out-of-season RSV outbreak investigation. The new surveillance platform fulfilled important objectives in all three domains of the mosaic framework and could serve for gathering additional information to fulfil more domain objectives. ConclusionThe new hospital laboratory surveillance platform provided essential data during the COVID-19 pandemic and beyond, fulfilled important domain objectives of the mosaic framework and could be adapted for the surveillance of other viruses.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 8.08.2024
Tilføjet 8.08.2024
This report describes ACIP recommendations for the use of the RSV vaccine for older adults.
Læs mereEduardo Azziz-Baumgartner, Avital Hirsch, Young M Yoo, Alon Peretz, David Greenberg, Yonat Shemer Avni, Aharona Glatman-Freedman, Michal Mandelboim, Adam MacNeil, Emily T Martin, Gabriella Newes-Adeyi, Mark Thompson, Arnold S Monto, Ran D Balicer, Min Z Levine and Mark A Katz
Eurosurveillance latest updates, 2.08.2024
Tilføjet 2.08.2024
BackgroundHealthcare personnel (HCP) are at high risk for respiratory infections through occupational exposure to respiratory viruses. AimWe used data from a prospective influenza vaccine effectiveness study in HCP to quantify the incidence of acute respiratory infections (ARI) and their associated presenteeism and absenteeism. MethodsAt the start and end of each season, HCP at two Israeli hospitals provided serum to screen for antibodies to influenza virus using the haemagglutination inhibition assay. During the season, active monitoring for the development of ARI symptoms was conducted twice a week by RT-PCR testing of nasal swabs for influenza and respiratory syncytial virus (RSV). Workplace presenteeism and absenteeism were documented. We calculated incidences of influenza- and RSV-associated ARI and applied sampling weights to make estimates representative of the source population. ResultsThe median age of 2,505 participating HCP was 41 years, and 70% were female. Incidence was 9.1 per 100 person-seasons (95% CI: 5.8–14.2) for RT-PCR-confirmed influenza and 2.5 per 100 person-seasons (95% CI: 0.9–7.1) for RSV illness. Each season, 18–23% of unvaccinated and influenza-negative HCP seroconverted. The incidence of seroconversion or RT-PCR-confirmed influenza was 27.5 per 100 person-seasons (95% CI: 17.8–42.5). Work during illness occurred in 92% (95% CI: 91–93) of ARI episodes, absence from work in 38% (95% CI: 36–40). ConclusionInfluenza virus and RSV infections and associated presenteeism and absenteeism were common among HCP. Improving vaccination uptake among HCP, infection control, and encouraging sick HCP to stay home are important strategies to reduce ARI incidence and decrease the risk of in-hospital transmission.
Læs mereECDC
ECDC COVID-19 updates, 29.07.2024
Tilføjet 29.07.2024
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mereMedscape Infectious Diseases, 24.07.2024
Tilføjet 24.07.2024
Merck\'s antibody-based shot met the main goal of a mid-to-late stage trial, when tested to protect infants against a disease caused by the respiratory syncytial virus (RSV),... Reuters Health Information
Læs mereMedscape Infectious Diseases, 12.07.2024
Tilføjet 12.07.2024
Important changes to vaccination recommendations for COVID, flu, RSV, and pneumococcal disease -- and what\'s behind the changes -- are summarized here. Medscape Internal Medicine
Læs mereMedscape Infectious Diseases, 3.07.2024
Tilføjet 3.07.2024
The RSV season is peaking earlier and entailing higher rates of hospitalization, according to Canadian data. Medscape Medical News
Læs mereMedscape Infectious Diseases, 28.06.2024
Tilføjet 28.06.2024
Moderna\'s mRNA vaccine mRESVIA has been recommended for a marketing authorization in the EU to protect against respiratory syncytial virus in older adults. Medscape Medical News
Læs mereMedscape Infectious Diseases, 28.06.2024
Tilføjet 28.06.2024
The U.S. CDC on Wednesday narrowed its recommendation for use of respiratory syncytial virus vaccines in older adults this year and held off on recommending their use for... Reuters Health Information
Læs mereMedscape Infectious Diseases, 4.06.2024
Tilføjet 4.06.2024
For the first time, an mRNA vaccine has been approved for an indication other than COVID-19. The vaccine will join a couple other immunizations currently on the market for respiratory syncytial virus. Medscape Medical News
Læs mereMorbidity and Mortality Weekly Report (MMWR), 31.05.2024
Tilføjet 31.05.2024
This report describes safety findings a year after the respiratory syncytial virus (RSV) vaccine was recommended for adults 60 and older.
Læs mereWei Cai, Sophie Köndgen, Kristin Tolksdorf, Ralf Dürrwald, Barbara Biere, Walter Haas, Thorsten Wolff, Silke Buda and Janine Reiche
Eurosurveillance latest updates, 17.05.2024
Tilføjet 17.05.2024
Medscape Infectious Diseases, 16.05.2024
Tilføjet 16.05.2024
Data raise questions about whether more testing for RSV and more vaccination are needed. Medscape Medical News
Læs mereECDC
ECDC COVID-19 updates, 4.05.2024
Tilføjet 4.05.2024
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
Læs mereECDC
ECDC COVID-19 updates, 26.04.2024
Tilføjet 26.04.2024
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
Læs mereMedscape Infectious Diseases, 19.04.2024
Tilføjet 19.04.2024
Last year saw more than 50 new drug approvals, many of which may help internists better manage several common conditions in their patients. Medscape Medical News
Læs mereECDC
ECDC COVID-19 updates, 15.04.2024
Tilføjet 15.04.2024
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels.
Læs mereECDC
ECDC COVID-19 updates, 12.04.2024
Tilføjet 12.04.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7 - 13 April 2024 and includes updates on measles, avian influenza, COVID-19, Mpox, seasonal influenza, RSV, cholera and shigellosis.
Læs mereECDC
ECDC Communicable Disease Threats Report, 12.04.2024
Tilføjet 12.04.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7 - 13 April 2024 and includes updates on measles, avian influenza, COVID-19, Mpox, seasonal influenza, RSV, cholera and shigellosis.
Læs mereSarah K Nørgaard, Jens Nielsen, Anne Christine Nordholm, Lukas Richter, Alena Chalupka, Natalia Bustos Sierra, Toon Braeye, Maria Athanasiadou, Theodore Lytras, Gleb Denissov, Oskari Luomala, Anne Fouillet, Isabelle Pontais, Matthias an der Heiden, Benedikt Zacher, Alina Weigel, Ivo Foppa, Kassiani Gkolfinopoulou, Ioannis Panagoulias, Anna Paldy, Tibor Malnasi, Lisa Domegan, Eva Kelly, Naama Rotem, Oksana Rakhlin, Francesca K de'Donato, Chiara Di Blasi, Patrick Hoffmann, Telma Velez, Kathleen England, Neville Calleja, Liselotte van Asten, Femke Jongenotter, Ana Paula Rodrigues, Susana Silva, Petra Klepac, Diana Gomez-Barroso, Inmaculada Leon Gomez, Ilias Galanis, Ahmed Farah, Rolf Weitkunat, Katarina Fehst, Nick Andrews, Tom Clare, Declan T Bradley, Mark G O'Doherty, Naoma William, Mark Hamilton, Bolette Søborg, Tyra G Krause, Nick Bundle and Lasse S Vestergaard
Eurosurveillance latest updates, 12.04.2024
Tilføjet 12.04.2024
Since the end of November 2023, the European Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate of 95.3 (95% CI: 91.7–98.9) excess all-cause deaths per 100,000 person-years for all ages. This excess mortality is seen in adults aged 45 years and older, and coincides with widespread presence of COVID-19, influenza and respiratory syncytial virus (RSV) observed in many European countries during the 2023/24 winter season.
Læs mereMedscape Infectious Diseases, 10.04.2024
Tilføjet 10.04.2024
Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60... Reuters Health Information
Læs mereECDC
ECDC COVID-19 updates, 8.04.2024
Tilføjet 8.04.2024
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels.
Læs mereWei Cai, Sophie Köndgen, Kristin Tolksdorf, Ralf Dürrwald, Ekkehard Schuler, Barbara Biere, Brunhilde Schweiger, Luise Goerlitz, Walter Haas, Thorsten Wolff, Silke Buda and Janine Reiche
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundNon-pharmaceutical interventions (NPIs) during the COVID-19 pandemic affected respiratory syncytial virus (RSV) circulation worldwide. AimTo describe, for children aged
Læs mereMedscape Infectious Diseases, 25.03.2024
Tilføjet 25.03.2024
Yale pulmonologist Denyse Lutchmansingh, MBBS, talks RSV vaccine recommendations and efficacy, prevention, risks, disease burden, and treatment. Medscape Infectious Diseases
Læs mereMedscape Infectious Diseases, 20.03.2024
Tilføjet 20.03.2024
Adult RSV infection can have serious consequences. These five things to know will help you recognize and protect the adult populations most vulnerable to severe disease. Medscape Infectious Diseases
Læs mereECDC
ECDC COVID-19 updates, 20.03.2024
Tilføjet 20.03.2024
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mereMedscape Infectious Diseases, 14.03.2024
Tilføjet 14.03.2024
With a maternal vaccine already on the market to protect newborns from RSV, the outlook for another looked promising, but latest phase 3 trial of a new candidate is now halted over safety concerns. Medscape Medical News
Læs mereMedscape Infectious Diseases, 14.03.2024
Tilføjet 14.03.2024
Almost 10,000 older adults die each year due to respiratory syncytial virus. Two new FDA-approved RSV vaccines may help lower that number, and also ease congestion in hospitals. Medscape
Læs mere